Evidence map›Paper›PMID 40272002›Full record

ArticleImmunotherapy2025

CD33-D2 isoform characterization for advancement of its therapeutic potential.

Vivek M Shastri, Srideshikan Sargur Madabushi, Susanta K Hui, Jatinder K Lamba

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vivek M ShastriDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Srideshikan Sargur MadabushiDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Susanta K HuiDepartment of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Jatinder K LambaDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL, USA.

Funding

University of Florida Health Cancer Center Support GrantP30CA247796 · NCI · UNIVERSITY OF FLORIDA · PI JI-HYUN LEE · 2023 to 2026
$10.9M
NCI NIH HHS P30 CA247796
6 · The paper itself

Abstract

purposeWhile CD33 directed immunotherapies have caught significant interest in recent years, the only approved antibody-drug conjugate targeting this antigen for AML is gemtuzumab ozogamicin, which targets the IgV-domain of CD33. Unfortunately, in its current form, these are not effective in a significant proportion of patients due to the presence of a splicing SNP resulting in the loss of IgV-domain. This, however, can be mitigated by targeting the IgC2-domain of CD33; thus, this study aimed to characterize CD33-D2 isoform using the recently developed CD33-D2-targeting antibody HL2541.

methodsGenetically engineered AML cell lines expressing CD33 isoforms were tested for antibody-bound internalization and response to GO

resultsHL2541-bound-CD33-D2 is internalized similar to CD33-FL upon binding the antibody component of GO. Co-existence of both isoforms compromises the internalization by >2.5-3-fold for each isoform in the AML cell lines, further resulting in 7-9.5-fold higher IC

conclusionThe results establish the relevance of targeting IgC domain as an alternative immunotarget to supplement AML chemotherapy.

Indexed as

ImmunotherapyLeukemia, Myeloid, AcuteSialic Acid Binding Ig-like Lectin 3AnimalsCell Line, TumorHumansMiceProtein IsoformsCD33 protein, humanProtein IsoformsSialic Acid Binding Ig-like Lectin 3Acute myeloid leukemiaantibodiesCD33immunotargetimmunotherapy

Identifiers

PMID40272002
PMCPMC12045573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.